The wild ride continued Thursday for
, whose implantable device for treating depression was flagged for clearance at the FDA in February. Cyberonics disclosed Wednesday night that the Senate Finance Committee is "examining the FDA's handling" of the device, which received an approvable letter Feb. 2 over the objections of an FDA advisory panel. The company says the committee seeks "certain information" but doesn't allege any wrongdoing on the company's part. Shares are off $5.20 to $33.67.
said it earned $300.5 million, or $1.61 a share, for the third quarter ended April 30, versus $264 million, or $1.33 a share, a year ago. Revenue for the quarter was $849.5 million. Excluding certain items, the company earned $289.9 million, or $1.55 a share. Analysts expected earnings of $1.55 a share on revenue of $843.2 million, according to Thomson First Call. For the full year, the company expects pro forma earnings of $1.96 to $1.99 a share on revenue of $2 billion to $2.02 billion. The company also announced its board has approved a 3 year stock repurchase program for up to $500 million. The stock was down $1.51 to $42.72 in premarket trading.
( HOTT) said it earned $5 million, or 11 cents a share, for the first quarter ended April, compared with $5.3 million, or 11 cents a share, a year ago. Revenue for the quarter was $149.8 million. As reported, same store sales increased 0.9% for the quarter versus an increase of 4% a year ago. Analysts expected earnings of 11 cents a share on revenue of $151.1 million. The stock was down 39 cents, or 1.81%, to $21.11 in after-hours trading.
posted first-quarter earnings of $22.7 million, or 61 cents a share, up from $15.1 million, or 41 cents a share, a year ago. Revenue for the quarter was $411.6 million. Excluding certain items the company earned 69 cents a share. Analysts expected earnings of 54 cents a share on revenue of $405.8 million. The full year, the company expects to earn $2.40 to $2.53 a share, compared with Wall Street's expectation of $2.46. The company also announced its board has approved a 3-for-2 stock split of its common shares and will be payable as a stock dividend. The stock was up $2.53, or 5.74%, to $46.58 in after-hours trading.
First quarter earnings at
Longs Drug Stores
( LDG) rose to $12.8 million, or 34 cents a share, from $9.2 million, or 25 cents a share, a year ago. Revenue for the quarter was $1.15 billion. Analysts expected earnings of 30 cents a share on revenue of $1.15 billion, according to Thomson First Call. The company said same store sales were down 1.2%. For the second quarter, the company expects to earn 30 to 38 cents a share, while for the full year the company forecasts earnings of $1.30 to $1.40 a share. Wall Street was expecting 34 cents a share for the second quarter and $1.32 a share for the full year. The stock was unchanged at $37.99.